| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial |
| Creator | Ychou et al. |
| Author | Marc Ychou |
| Author | Michel Rivoire |
| Author | Simon Thezenas |
| Author | Rosine Guimbaud |
| Author | Anne Mercier-Blas |
| Author | Laurent Mineur |
| Author | Eric Francois |
| Author | Faiza Khemissa |
| Author | Marion Chauvenet |
| Author | Reza Kianmanesh |
| Author | Marianne Fonck |
| Author | Philippe Houyau |
| Author | Thomas Aparicio |
| Author | Marie-Pierre Galais |
| Author | Franck Audemar |
| Author | Eric Assenat |
| Author | Evelyne Lopez-Crapez |
| Author | Claire Jouffroy |
| Author | Antoine Adenis |
| Author | René Adam |
| Author | Olivier Bouché |
| Abstract | BACKGROUND: Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be converted to resectable with chemotherapy plus a targeted therapy. We assessed which of chemotherapy doublet (2-CTx) or triplet (3-CTx), combined with targeted therapy by RAS status, would be better in this setting. METHODS: PRODIGE 14 was an open-label, multicenter, randomised Phase 2 trial. CRC patients with initially defined unresectable liver-only metastases received either, 2-CTx (FOLFOX or FOLFIRI) or 3-CTx (FOLFIRINOX), plus bevacizumab/cetuximab by RAS status. The primary endpoint was to increase the R0/R1 liver-resection rate from 50 to 70% with the 3-CTx. RESULTS: Patients (n?=?256) were mainly men with an ECOG PS of 0, and a median age of 60 years. In total, 109 patients (42.6%) had RAS-mutated tumours. After a median follow-up of 45.6 months, the R0/R1 liver-resection rate was 56.9% (95% CI: 48-66) with the 3-CTx versus 48.4% (95% CI: 39-57) with the 2-CTx (P?=?0.17). Median overall survival was 43.4 months with 3-CTx versus 40 months with 2-CTx. CONCLUSION: We failed to increase from 50 to 70% the R0/R1 liver-resection rate with the use of 3-CTx combined with bevacizumab or cetuximab by RAS status in CRC patients with initially unresectable liver metastases. |
| Publication | British Journal of Cancer |
| Volume | 126 |
| Issue | 9 |
| Pages | 1264-1270 |
| Date | 2022-05 |
| Journal Abbr | Br J Cancer |
| Language | eng |
| DOI | 10.1038/s41416-021-01644-y |
| ISSN | 1532-1827 |
| Library Catalog | PubMed |
| Extra | PMID: 34992255 PMCID: PMC9042909 |
| Tags | Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Cetuximab, Colorectal Neoplasms, Fluorouracil, Humans, Leucovorin, Liver Neoplasms, Male, Middle Aged, Pancreatic Neoplasms |
| Date Added | 2022/08/30 - 16:10:29 |
| Date Modified | 2024/10/10 - 16:31:38 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
